# Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

> **NCT02121639** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Southampton NHS Foundation Trust** · enrollment: 160 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** AZD5363

## Key facts

- **NCT ID:** NCT02121639
- **Lead sponsor:** University Hospital Southampton NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-29
- **Primary completion:** 2020-10-08
- **Final completion:** 2021-09-13
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2022-05-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02121639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02121639, "Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02121639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*